Quidel Moves Beyond Point-Of-Care Focus With Diagnostic Hybrids Buy
This article was originally published in The Gray Sheet
Executive Summary
Point-of-care-testing firm Quidel hopes to greatly expand its hospital and reference laboratory customer base, and become less reliant on flu season revenues, with its $130 million acquisition of Diagnostic Hybrids